INSO BIOSCIENCES INC

Flagstaff, AZ · Founded 2018 · CIK 0001906426 · Medtech · Private

Platform technologies for biological sample preparation

inso.bio →
Grants
$676K
3 awards
Sector median: 1
Raised
$2.5M
2 Form D · Apr 2026
5 months since last filing
Contracts
$400K
1 award · Health and Human S
#402 of 4531 in medtech
Patents
13
0 granted · 13 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Microfluidic Technology for Single Cell Multi-Omic Sample Preparation$250,000
Federal grantDepartment of Health and Human Services · Phase I · Facile Method for Enhanced Pathogen Detection$250,894
Private capital raisedForm D · SEC$1,775,000
Federal contractDepartment of Health and Human Services · SBIR Topic 439 - Advanced Sample Processing Platforms For Downstream Single-cell Multi-omic Analysis$399,674
Federal grantDepartment of Agriculture · **awards Issued Prior To January 20, 2025, Were Funded Under Previous Administrations And May Not Reflect The Priorities And Policies Of The Current Administration.** Advancements In Plant Genomics Have Improved Plant Breeding Efforts, But Genomic Sample Preparation For The Newest Sequencing Technologies (long-read Sequencing)remains A Key Bottleneck. Preparation Of Plant Genomes Into High-molecular Weight (hmw)dna Is More Challenging Than Both Mammalian Sample Preparation And Short-read Sample $174,709
Private capital raisedForm D · SEC$750,000
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
399QUANTITATIVE IMAGING SYSTEMS LLC$400K—
400ACOUSTIIC, INC.$400K—
401EISANA CORP$400K$125K
402INSO BIOSCIENCES INC$400K$2.5M
403VOXIMETRY INC$397K$4.6M
404Opko Health, Inc.$387K$206M
405DXRAY, INC.$378K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Adam BisogniDirector
  • Harvey TianDirector · Executive Officer

Patents

USPTO · 0 granted of 13
  • Devices, Methods, And Systems For Enriching Cellular Samples By Physical Propertiesapplication
  • DEVICES AND METHODS FOR mtDNA EXTRACTIONapplication
  • Devices, Methods, And Systems For Extracting Genomic Dna From Cell Samples With Tunable Size Selectionapplication
  • DEVICES AND METHODS FOR mtDNA EXTRACTIONapplication
  • DEVICES AND METHODS FOR mtDNA EXTRACTIONapplication
  • Devices, Methods, And Systems For Enriching Cellular Samples By Physical Propertiesapplication
  • Devices, Methods, And Systems For Extracting Genomic Dna From Cell Samples With Tunable Size Selectionapplication
  • Devices, Methods, And Systems For Enriching Cellular Samples By Physical Propertiesapplication
  • Devices, Methods, And Systems For Extracting Genomic Dna From Cell Samples With Tunable Size Selectionapplication
  • Methods And Apparatus For Extracting Or Separating Nucleic Acids From Biological Samplesapplication
  • Devices, Methods, And Systems For Extracting Genomic Dna From Cell Samples With Tunable Size Selectionapplication
  • Methods And Apparatus For Extracting Or Separating Nucleic Acids From Biological Samplesapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.